Sep 22, 2026 08:00AM
Aug 12, 2026 04:29PM
Jun 23, 2026 08:00AM
May 13, 2026 04:35PM
Apr 23, 2026 08:00AM
Apr 15, 2026 08:03AM
Apr 15, 2026 08:00AM Reviva Announces Letter to Shareholders
Mar 30, 2026 06:05AM
Jan 8, 2026 08:03AM
Jan 8, 2026 08:00AM
Jan 5, 2026 04:35AM
Dec 24, 2025 06:44AM
Dec 23, 2025 08:03AM
Dec 23, 2025 08:00AM Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Nov 13, 2025 04:05PM
Nov 10, 2025 08:00AM
Oct 27, 2025 06:50AM
Sep 15, 2025 09:04AM
Aug 14, 2025 04:25PM
Jun 2, 2025 07:02AM
Jun 2, 2025 07:00AM Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
May 15, 2025 04:05PM
Dec 20, 2024 07:01AM
Dec 20, 2024 07:00AM
Dec 16, 2024 08:05AM
Dec 16, 2024 08:00AM
Nov 14, 2024 05:25PM
Nov 12, 2024 08:06AM Reviva Pharmaceuticals (RVPH) Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Nov 12, 2024 08:00AM
Sep 9, 2024 08:04AM
Sep 9, 2024 08:00AM
Aug 27, 2024 08:00AM
Aug 14, 2024 08:00AM
Aug 6, 2024 08:02AM
Aug 6, 2024 08:00AM Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis
Jul 11, 2024 10:33AM
Jul 9, 2024 08:12AM
Jul 9, 2024 08:00AM
May 29, 2024 04:45PM
May 28, 2024 08:01AM
May 28, 2024 08:00AM
May 15, 2024 08:00AM Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
May 14, 2024 08:00AM
May 13, 2024 08:00AM
May 9, 2024 08:00AM
Apr 15, 2024 08:31AM
Apr 15, 2024 08:30AM
Apr 15, 2024 08:05AM
Mar 28, 2024 08:00AM Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
Mar 26, 2024 08:00AM

334,272 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All